© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 1

“RDA: better chemotherapy management”

Investor PresentationApril 2013

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 2

Would you prefer to know if your

chemotherapy is working or not NOW

Would you like to endure 26 weeks of chemotherapy

side effects?OR

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 3

Problem: Adverse Side Effects 50% of breast cancer patients

receive chemotherapy 75% of chemo patients derive no

long term benefit All patients suffer adverse side

effects

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 4

Solution:RDA™ improved chemotherapy management

First “Real Time” chemotherapy guidance tool Only prognostic test to measure response to

chemotherapy early in treatment Discovered in clinical trial (NCIC MA.22) Protected by broad patents

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 5

Benefits for Patients, Physicians and Payers

For non responding patients, treatment can be altered quicklySignificant reduction in adverse effectsSwitch to alternate treatment improves survival benefit

Objective & useful tool for physiciansCost savings for healthcare payers ($20k - $60K / patient)

Maureen E. Trudeau MD, FRCPCHead, Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Centre, Head, Systemic Therapy Program, Odette Cancer Centre, Toronto, Canada

“RDA holds the prospect of providing oncologists with an extremely valuable method for managing the chemotherapy of their breast cancer patients”

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 6

Technology : RNA Disruption Assay (RDA™)

National Cancer Institute of Canada breast cancer trial (MA.22)

Clear discrimination between responders and non-responders

RDA strongly correlates with pathological complete response (pCR) at end of therapy

Negative Predictive Value = 0.99

False Negative 1%

RDA™ Performance Characteristics

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 7

RDA™ Clinical ScoringRDA Score Clinical Guidance

1 Patient is a non-responder, chemotherapy is not working. Consider alternate approach

NPV 0.99 False Negative Rate of 0.01

2 Patient is a partial responder – chemotherapy should be continued

3 High level of RNA structural dysfunction – chemotherapy is working. Patient 3x more likely to achieve pCR than untested cohort

PPV 0.17

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 8

RDA: Clinical SystemChemotherapy selected Chemotherapy infusion Breast tumour biopsy

Fine Needle Aspirate,2 samples

Tumour RNA FixativeRNA Disruption analysed at Rna DIAGNOSTICS central lab

Raw data analysed by Rna DIAGNOSTICS using proprietary algorithms. Results transmitted to clinician

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 9

Management TeamManagement CEO: Dr. Ken Pritzker, MD, FRCPC

Former Chief Pathology & Lab Medicine, Mount Sinai Hospital, Toronto, Cancer diagnostics expert CSO: Dr. Amadeo Parissenti, PhD

Cancer Research Scientist, Laurentian University VP Corporate Development: John Connolly, MBA

Former partner at MDS Capital Corp. – 15 year Medtech entrepreneur CFO: John Jordan, MBA, CMA, CPA, ABV

Financial executive, experienced working with high growth technology companies

Clinical Advisory Board Maureen Trudeau, MA, MD, FRCPC - Head , Medical Oncology, Sunnybrook

Health Sciences, Toronto, Canada Michael Untch, MD, PhD– Head , German Breast Group, Berlin, Germany Gunter von Minckwitz, MD, PhD – Chairman, German Breast Group, Frankfurt,

Germany Harry Bear, MD, PhD – Principal Investigator, NSABP, Virginia Commonwealth

University, USA

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 10

Market Opportunity in Breast Cancer

Japan & Australia

USA & Canada

Europe

Total Developed World

BRIC

Total

59,236

205,446

425,147

726,199

379,738

1,105,937

Developed World & BRIC Countries Breast Cancer

New Case Incidence 2008(Source: WHO GLOBOCAN 2008)

Size of Breast Cancer Market

$525M# of Patients per year in the developed world

350,000Sales Forecast

by 2018

$100 M

Total Addressable Market

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 11

Competition :Oncologists need better tools

Physical Exam

Physical Exams do not predict efficacy

Imaging Over estimates efficacy

Too late to impact clinical decision making

Gene panels predict probability of 10 year recurrence

Don’t predict efficacy

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 12

Sales Forecast

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 13

Rna Diagnostics Inc.

Unique solution for serious cancer problem Large market - $500M in Breast Cancer Strong IP and clinical data Clinical trials underway Rapid route to market

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 14

“RDA: better chemotherapy management”

Investor PresentationApril 2013